Human Jade-1/PHF17 Antibody (658005)

R&D Systems | Catalog # MAB6275

R&D Systems

Key Product Details

Species Reactivity

Human

Applications

Western Blot, Immunocytochemistry

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2B Clone # 658005
View all Jade-1/PHF17 Primary Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human JADE-1/PHF-17
Met1-Ser137
Accession # Q6IE81

Specificity

Detects human JADE-1/PHF-17 in direct ELISAs and Western blots. In Western blots, approximately 50% cross-reactivity with recombinant human Jade-2/PHF15 is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2B

Scientific Data Images for Human Jade-1/PHF17 Antibody (658005)

Detection of Human Jade-1/PHF17 antibody by Western Blot.

Detection of Human Jade‑1/PHF17 by Western Blot.

Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line and Ramos human Burkitt's lymphoma cell line. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human Jade‑1/PHF17 Monoclonal Antibody (Catalog # MAB6275) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for Jade‑1/PHF17 at approximately 92 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Jade-1/PHF17 antibody in HeLa Human Cell Line by Immunocytochemistry (ICC).

Jade‑1/PHF17 in HeLa Human Cell Line.

Jade-1/PHF17 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using Mouse Anti-Human Jade-1/PHF17 Monoclonal Antibody (Catalog # MAB6275) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to nuclei and cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Detection of Jade-1/PHF17 by Western Blot

Detection of Jade-1/PHF17 by Western Blot

ERBB2 and JADE1 knockdown inhibits cell proliferation in HEPM cells. (A) Quantitative RT-PCR for ERBB2 after treatment with ERBB2 siRNA for 24 h in HEPM cells. ***p < 0.001. (B) Immunoblotting of ERBB2 and GAPDH in HEPM cells treated with an ERBB2 siRNA for 48 h. Representative images from two independent experiments are shown. (C) Quantitative RT-PCR for JADE1 after treatment with JADE1 siRNA for 24 h in HEPM cells. ***p < 0.001. (D) Immunoblotting of JADE1 and GAPDH in HEPM cells treated with JADE1 siRNA for 48 h. Representative images from two independent experiments are shown. (E) Cell proliferation assays in HEPM cells treated with an ERBB2 or JADE1 siRNA for 24, 48, or 72 h. **p < 0.01, ***p < 0.001. Each treatment group was compared with a control siRNA group at each indicated day. (F) Immunoblotting of CCND1, CDKN1B, and GAPDH in HEPM cells treated with siRNA for ERBB2 or JADE1 for 48 h. Representative images from two independent experiments are shown. (G)ERBB2 expression following overexpression in HEPM cells. **p < 0.01. (H)JADE1 expression following overexpression in HEPM cells. ***p < 0.001. (I) Cell proliferation assays in HEPM cells overexpressing ERBB2 and/or JADE1 for 24, 48, or 72 h. **p < 0.01, ***p < 0.001. Each treatment group was compared with control vector (mock) group at each indicated day. ##p < 0.01 vs. mock + atRA at day 3. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33585479), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Jade-1/PHF17 by Western Blot

Detection of Jade-1/PHF17 by Western Blot

atRA induces miR-4680-3p expression in HEPM cells. (A) Quantitative RT-PCR for the indicated miRs after treatment of HEPM cells with atRA for 1 or 3 days. ***p < 0.001. (B) Quantitative RT-PCR for the indicated genes after treatment of HEPM cells with atRA for 1 or 3 days. *p < 0.05, **p < 0.01. Each treatment group was compared with a control vehicle group at each indicated day. (C) Immunoblotting for ERBB2, JADE1, phosphorylated ERK1/2 (P-ERK1/2), ERK1/2, phosphorylated mTOR (P-mTOR), mTOR, and GAPDH in HEPM cells treated with 30 μM atRA for 72 h. Representative images from two independent experiments are shown. (D) Immunocytochemical analysis of ERBB2 and JADE1 (green) in HEPM cells treated with 30 μM atRA for 72 h. Nuclei were counterstained with DAPI (blue). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33585479), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Jade-1/PHF17 by Western Blot

Detection of Jade-1/PHF17 by Western Blot

Normalization of miR-4680-3p expression restores atRA-induced cell proliferation suppression in HEPM cells. (A) Cell proliferation assays in HEPM cells treated with 30 μM atRA, with/without miR-4680-3p inhibitor, for 24, 48, or 72 h. ***p < 0.001 vs. control inhibitor + vehicle at each indicated day. ##p < 0.01 vs. control inhibitor + atRA at indicated day. (B) BrdU staining (red) in HEPM cells after treatment with 30 μM atRA, with/without miR-4680-3p inhibitor, for 72 h. Nuclei were counterstained with DAPI (blue). (C) Graph shows the quantification of BrdU-positive cells. **p < 0.01 vs. control inhibitor + vehicle. ##p < 0.01 vs. control inhibitor + atRA. (D) Quantitative RT-PCR for the indicated genes after treatment with atRA, with/without miR-4680-3p inhibitor, for 24 h in HEPM cells. **p < 0.01 vs. control inhibitor + vehicle. ##p < 0.01 vs. control inhibitor + atRA. (E) Immunoblotting of ERBB2, JADE1, phosphorylated ERK1/2 (P-ERK1/2), ERK1/2, CCND1, CDKN1B, and GAPDH in HEPM cells treated with 30 μM atRA, with/without miR-4680-3p inhibitor, for 72 h. Representative images from two independent experiments are shown. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33585479), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human Jade-1/PHF17 Antibody (658005)

Application
Recommended Usage

Immunocytochemistry

8-25 µg/mL
Sample: Immersion fixed HeLa human cervical epithelial carcinoma cell line

Western Blot

2 µg/mL
Sample: HeLa human cervical epithelial carcinoma cell line and Ramos human Burkitt's lymphoma cell line

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Sterile PBS to a final concentration of 0.5 mg/mL. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: Jade-1/PHF17

Jade-1 (Gene for Apoptosis and Differentiation in Epithelia; also PHF17) is a 94 kDa member of the JADE family of proteins. It is expressed in renal tubule cells as well as embryonic primitive streak (in mouse). Initially, Jade-1 was described as a proapoptotic tumor suppressor. Jade-1 also interacts with the HBO1 complex to specifically acetylate nucleosome histones, thus acting as a transcriptional activator that likely impacts DNA replication, recombination and repair. Human Jade-1 is 842 amino acids (aa) in length. It contains one PEST domain with multiple Ser phosphorylation sites (aa 5-28), and two PHD Zinc fingers (aa 203-253 and 312-371) that are required for histone acetylation. There are two splice variants, one that is 61-64 kDa in size and contains a 7 aa substitution for aa 503-842, and another that shows a deletion of aa 99-110. Over aa 1-137, human Jade-1 shares 96% aa identity with mouse Jade-1.

Alternate Names

Jade1, PHF17

Entrez Gene IDs

79960 (Human); 269424 (Mouse); 310352 (Rat)

Gene Symbol

JADE1

UniProt

Q6IE81

Additional Jade-1/PHF17 Products

Product Documents for Human Jade-1/PHF17 Antibody (658005)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human Jade-1/PHF17 Antibody (658005)

For research use only

Related Research Areas

Epigenetics

Citations for Human Jade-1/PHF17 Antibody (658005)

Customer Reviews for Human Jade-1/PHF17 Antibody (658005)

There are currently no reviews for this product. Be the first to review Human Jade-1/PHF17 Antibody (658005) and earn rewards!

Have you used Human Jade-1/PHF17 Antibody (658005)?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies